Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asuragen has globally launched its Signature LTx, a multiplexed reverse transcription PCR assay that detects nine common leukemia-associated translocations.
Subscribe to our email newsletter
The assay is performed on a Luminex cytometer using a multi-probe liquid bead array method. The liquid bead array format provides comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.
The Signature LTx (RUO) panel is utilized for the rapid detection and identification of the fusion transcripts from common chromosome translocations and abnormalities associated with CML, AML, APL, and ALL. The Signature LTx (RUO) product is available immediately to laboratories throughout the world. This product launch marks the continued globalization of the Signature product portfolio, including reagents for cystic fibrosis and Ashkenazi Carrier Panel.
Tim Stenzel, vice president R&D, and chief medical officer of Asuragen, said: “The Signature LTx panel is more sensitive than standard karyotype and FISH analysis, and because it is highly multiplexed, eliminates the need for analysis on numerous assays and platforms.”